Serum Lipidomics Profiling to Identify Biomarkers for Non-Small Cell Lung Cancer

Table 5

Statistical analysis of differential lipids to distinguish LBD from HC group.

Peak	Lipid	Polarity	VIP value	Fold Change	p value	Peak	Lipid	Polarity	VIP value	Fold Change	p value
1	PC(P-18:0/15:1)	POS	2.19	13.46	<0.001	23	PC(16:0/20:5)	NEG	1.40	1.73	<0.001
2	PC(16:0/24:4)	POS	1.35	1.65	<0.001	24	PE(16:0/22:6)	NEG	2.04	1.71	<0.001
3	PC(18:2/24:4)	POS	1.24	1.61	<0.001	25	PE(18:0/0:0)	NEG	1.70	1.71	<0.001
4	PC(18:1/24:4)	POS	1.08	1.53	<0.001	26	PE(18:0/20:4)	NEG	1.74	1.70	<0.001
5	PC(18:3/26:2)	POS	1.15	1.52	<0.001	27	PE(17:0/18:1)	NEG	1.97	1.68	<0.001
6	PI(18:1/18:2)	NEG	1.91	2.34	0.006	28	PI(17:0/20:4)	NEG	1.70	1.67	<0.001
7	PE(20:1/16:0)	NEG	1.89	2.05	<0.001	29	PI(18:0/22:5)	NEG	1.93	1.65	<0.001
8	PI(16:0/16:1)	NEG	1.66	2.05	0.003	30	PC(20:5/20:4)	NEG	1.75	1.64	<0.001
9	PE(18:0/22:5)	NEG	2.20	1.98	<0.001	31	PC(20:5/0:0)	NEG	1.41	1.63	<0.001
10	PE(16:0/20:5)	NEG	1.82	1.92	<0.001	32	PC(18:0/22:5)	NEG	2.04	1.63	<0.001
11	PI(18:0/22:4)	NEG	2.00	1.91	<0.001	33	PE(22:5/18:0)	NEG	1.60	1.62	<0.001
12	PE(18:1/20:4)	NEG	1.69	1.88	<0.001	34	PG(24:0/18:0)	NEG	2.03	1.60	<0.001
13	PE(20:1/24:1)	NEG	1.98	1.88	<0.001	35	PI(16:0/22:6)	NEG	1.53	1.59	<0.001
14	PI(16:0/22:5)	NEG	1.66	1.87	<0.001	36	PC(18:0/22:4)	NEG	1.70	1.59	<0.001
15	PI(16:0/20:5)	NEG	1.91	1.85	<0.001	37	PE(18:0/20:3)	NEG	1.85	1.58	<0.001
16	PE(16:0/18:3)	NEG	1.93	1.83	<0.001	38	PI(18:0/20:3)	NEG	1.59	1.56	<0.001
17	PE(16:0/20:4)	NEG	1.47	1.80	<0.001	39	PE(18:3/0:0)	NEG	1.62	1.54	<0.001
18	PE(22:6/16:0)	NEG	1.53	1.78	<0.001	40	PE(20:3/0:0)	NEG	1.57	1.52	<0.001
19	PC(P-18:0/4:0)	NEG	1.48	1.78	<0.001	41	PC(16:1/0:0)	NEG	1.82	1.52	<0.001
20	PE(18:1/22:6)	NEG	1.62	1.76	<0.001	42	PC(18:0/20:3)	NEG	1.58	1.51	<0.001
21	PE(16:0/0:0)	NEG	1.76	1.75	<0.001	43	PC(20:1/22:6)	NEG	1.58	1.50	<0.001
22	PE(18:0/18:2)	NEG	1.52	1.75	<0.001	44	PE(20:5/0:0)	NEG	1.48	1.50	<0.001

LBD, lung benign disease; HC, healthy controls.